Materias dentro de su búsqueda.
Mostrando 2,461 - 2,480 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.27s Limitar resultados
  1. 2461
    “…PURPOSE: The optimal duration of first-line trastuzumab (T) treatment for de novo stage IV HER2-positive metastatic breast cancer (MBC) patients after complete response (CR) is not known. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
  2. 2462
    “…Activation of HER2 in normal lung fibroblasts led to a more invasive genetic program and worsened fibroblast invasion and lung fibrosis, while antagonizing HER2 signaling blunted fibroblast invasion and ameliorated lung fibrosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts
  3. 2463
    “…However, HER2 levels were not related to the gender and smoking history of patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer
  4. 2464
    “…Among the EGFR family TKIs, canertinib, a dual EGFR/HER2 inhibitor, showed the best inhibitory effect on the migration and viability of BCAR4 fusion-overexpressing cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
  5. 2465
    “…The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
  6. 2466
    “…PURPOSE: To develop and validate a clinical-radiomics nomogram based on radiomics features and clinical risk factors for identification of human epidermal growth factor receptor 2 (HER2) status in patients with breast cancer (BC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: A multicenter study
  7. 2467
    “…The 21-gene recurrence score assay has been validated as a predictive biomarker in early-stage HR+ and HER2-breast cancer. It is not indicated for use in HER2+ disease based on national guidelines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
  8. 2468
    “…We compared the cost-effectiveness of T-DXd and T-DM1 for patients with HER2-positive mBC pretreated with anti-HER2 antibodies and a taxane from the perspectives of the United States (US) and China. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
  9. 2469
    “…However, many patients experience disease progression with HER2-targeted therapy; hence, new anti-HER2 drugs keep being developed, significantly reducing HER2 resistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
  10. 2470
    “…The best optimized V-FeBP MSC demonstrates the low HER and OER overpotentials of 52 and 180 mV at 50 mA/cm(2) in 1 M KOH in a three-electrode system. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vanadium-Doped FeBP Microsphere Croissant for Significantly Enhanced Bi-Functional HER and OER Electrocatalyst
  11. 2471
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
  12. 2472
    “…BACKGROUND: Preclinical and clinical data support potential synergy between anti-HER2 therapy plus immune checkpoint blockade. The safety and tolerability of trastuzumab emtansine (T-DM1) combined with pembrolizumab is unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
  13. 2473
    “…The overexpression of HER2 in breast cancer is a classic example for molecular targeted therapy, and it has been shown that classical anti-HER2 therapeutics were only effective in patients with HER2 overexpressing tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom: Konsequenzen für die histopathologische Diagnostik
  14. 2474
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeted Delivery of Doxorubicin Utilizing Chitosan Nanoparticles Surface Functionalized with Anti Her2 Trastuzumab [Corrigendum]
  15. 2475
    “…The human epithelial growth factor receptor 2 (Her-2) has been identified as a new therapeutic target in medical oncology. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
  16. 2476
    “…CONCLUSIONS: The prevalence of HER2-neu over expression in newly diagnosed early or metastatic GC patients seemed to be high in Lebanon. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients
  17. 2477
    “…Benefit/risk analysis does not support further evaluation of this combination in the treatment of HR+, HER2− MBC.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
  18. 2478
    “…We analyzed transcriptomic and genomic data of ER+/HER2− breast cancers with in silico RS < 26 from TCGA (n = 530), two microarray cohorts (A: n = 865; B: n = 609), the METABRIC (n = 867), and the SCAN-B (n = 1636) datasets. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
  19. 2479
    “…The current clinical management model of HER2-positive breast cancers is commonly based on guidelines, which in turn are based on the design and outcome of clinical trials. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
  20. 2480
    “…SIMPLE SUMMARY: HER2 mRNA expression is emerging as a powerful predictive biomarker of anti-HER2 drug activity in the treatment of HER2-positive breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
Herramientas de búsqueda: RSS